Resource Summary Report

Generated by NIF on Apr 18, 2025

ChemoCentryx

RRID:SCR_003976
Type: Tool

Proper Citation

ChemoCentryx (RRID:SCR_003976)

Resource Information

URL: http://www.chemocentryx.com/

Proper Citation: ChemoCentryx (RRID:SCR_003976)

Description: A biopharmaceutical company focused exclusively on discovering, developing and commercializing orally-administered therapeutics to treat autoimmune diseases, inflammatory disorders and cancer. Each drug candidate is a small molecule designed to target a specific chemokine or chemo-attractant receptor, thereby blocking the inflammatory response driven by that particular chemokine while leaving the rest of the immune system unaffected.

Synonyms: ChemoCentryx Inc, ChemoCentryx Inc.

Resource Type: commercial organization

Keywords: biopharmaceutical, oral administration, medicine, small molecule, chemokine, chemo-attractant receptor, clinical, drug, oral drug

Related Condition: Autoimmune disease, Inflammatory disorder, Cancer

Funding:

Resource Name: ChemoCentryx

Resource ID: SCR_003976

Alternate IDs: nlx_158383, grid.452218.8, ISNI: 0000 0004 0408 7502

Alternate URLs: https://ror.org/04gp12571

Record Creation Time: 20220129T080222+0000

Record Last Update: 20250410T065103+0000

Ratings and Alerts

No rating or validation information has been found for ChemoCentryx.

No alerts have been found for ChemoCentryx.

Data and Source Information

Source: SciCrunch Registry

Usage and Citation Metrics

We found 43 mentions in open access literature.

Listed below are recent publications. The full list is available at NIF.

Geetha D, et al. (2024) Efficacy and safety of avacopan in patients with ANCA-associated vasculitis receiving rituximab in a randomised trial. Annals of the rheumatic diseases, 83(2), 223.

Lazarevic I, et al. (2023) The choroid plexus acts as an immune cell reservoir and brain entry site in experimental autoimmune encephalomyelitis. Fluids and barriers of the CNS, 20(1), 39.

Sigmund EC, et al. (2023) Reassessing the adrenomedullin scavenging function of ACKR3 in lymphatic endothelial cells. PloS one, 18(5), e0285597.

Dawson JRD, et al. (2023) Molecular determinants of antagonist interactions with chemokine receptors CCR2 and CCR5. bioRxiv : the preprint server for biology.

Gencer S, et al. (2022) Endothelial ACKR3 drives atherosclerosis by promoting immune cell adhesion to vascular endothelium. Basic research in cardiology, 117(1), 30.

Somebang K, et al. (2021) CCR2 deficiency alters activation of microglia subsets in traumatic brain injury. Cell reports, 36(12), 109727.

Luo Y, et al. (2021) Enzalutamide-Resistant Progression of Castration-Resistant Prostate Cancer Is Driven via the JAK2/STAT1-Dependent Pathway. Frontiers in molecular biosciences, 8, 652443.

Wei ST, et al. (2021) Gain of CXCR7 function with mesenchymal stem cell therapy ameliorates experimental arthritis via enhancing tissue regeneration and immunomodulation.

Stem cell research & therapy, 12(1), 314.

Cui XY, et al. (2021) Tissue factor pathway inhibitor upregulates CXCR7 expression and enhances CXCL12-mediated migration in chronic lymphocytic leukemia. Scientific reports, 11(1), 5127.

Sigmund EC, et al. (2021) Lymphatic endothelial-cell expressed ACKR3 is dispensable for postnatal lymphangiogenesis and lymphatic drainage function in mice. PloS one, 16(4), e0249068.

Pluchino N, et al. (2020) CXCR4 or CXCR7 antagonists treat endometriosis by reducing bone marrow cell trafficking. Journal of cellular and molecular medicine, 24(4), 2464.

Flood ED, et al. (2020) Endogenous Chemerin from PVAT Amplifies Electrical Field-Stimulated Arterial Contraction: Use of the Chemerin Knockout Rat. International journal of molecular sciences, 21(17).

Demircioglu F, et al. (2020) Cancer associated fibroblast FAK regulates malignant cell metabolism. Nature communications, 11(1), 1290.

Wei ST, et al. (2020) Atypical chemokine receptor ACKR3/CXCR7 controls postnatal vasculogenesis and arterial specification by mesenchymal stem cells via Notch signaling. Cell death & disease, 11(5), 307.

Zhu Y, et al. (2020) Chemokine receptor CXCR7 non-cell-autonomously controls pontine neuronal migration and nucleus formation. Scientific reports, 10(1), 11830.

Williams JL, et al. (2020) Astrocyte-T cell crosstalk regulates region-specific neuroinflammation. Glia, 68(7), 1361.

Mohebnasab M, et al. (2019) Current and Future Approaches for Monitoring Responses to Anti-complement Therapeutics. Frontiers in immunology, 10, 2539.

Li N, et al. (2019) LPS-induced CXCR7 expression promotes gastric Cancer proliferation and migration via the TLR4/MD-2 pathway. Diagnostic pathology, 14(1), 3.

Kumar JD, et al. (2019) Chemerin acts via CMKLR1 and GPR1 to stimulate migration and invasion of gastric cancer cells: putative role of decreased TIMP-1 and TIMP-2. Oncotarget, 10(2), 98.

Miao Z, et al. (2018) CCR2 antagonism leads to marked reduction in proteinuria and glomerular injury in murine models of focal segmental glomerulosclerosis (FSGS). PloS one, 13(3), e0192405.